Wegovy Not as Effective as Mounjaro? Here's What the Evidence Actually Shows

What the trial data actually say about relative effectiveness

The clearest evidence comes from SURMOUNT-5, a 72-week open-label trial that randomised 751 adults with obesity (and no diabetes) to either tirzepatide or semaglutide 2.4mg. Tirzepatide produced significantly greater average weight reduction. That sits alongside earlier single-medicine trials: SURMOUNT-1 reported roughly 20–21% average loss at the 15mg tirzepatide dose, while the STEP 1 trial recorded around 15% at semaglutide 2.4mg, as published in the New England Journal of Medicine. NICE's appraisal of tirzepatide (TA1026) noted indirect comparisons also favour tirzepatide over semaglutide.

These are averages across diverse trial populations. Individual responses vary considerably, and some people lose substantially more or less than any mean figure. Dose also matters: the higher 7.2mg Wegovy dose, approved by the MHRA in early 2026, recorded around 20.7% average loss in trials, closing the gap with tirzepatide 15mg meaningfully. If you want a fuller look at whether Wegovy is as effective as Mounjaro at each dose level, the tirzepatide and semaglutide head-to-head breakdown covers the evidence in detail.

The short version: on average, Mounjaro outperforms standard-dose Wegovy. But "average" isn't a prescription.

How the two medicines differ in mechanism (and why it might matter to you

Mounjaro activates two gut-hormone receptors) GIP and GLP-1, simultaneously. Wegovy targets only GLP-1. Both slow gastric emptying and reduce appetite, but the dual-agonist action of tirzepatide appears to produce an additive effect on weight. The NHS medicines information for tirzepatide and for semaglutide describes each mechanism plainly if you want to read the patient-facing summaries side by side, that's a check you can do in under a minute.

In practice, both medicines share a broadly similar side-effect profile: nausea, diarrhoea, constipation, and reflux are the most commonly reported, typically most noticeable after starting or moving to a higher dose, and often settling within a couple of weeks. The pattern is GI-led for both. What differs is the titration schedule, tirzepatide starts at 2.5mg and is stepped up by the prescriber roughly every four weeks through six available strengths; semaglutide begins at 0.25mg and climbs through five steps to 2.4mg (or 7.2mg under the newer approval). Neither schedule should be self-managed; the prescriber sets the pace.

One practical distinction worth knowing: MHRA guidance advises women on tirzepatide who take an oral contraceptive pill to use an additional non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because absorption may be affected. There is no equivalent evidence-based recommendation for semaglutide. This is a small but clinically relevant difference if it applies to you.

A side-by-side reference for the key facts

Numbers on their own can mislead without context, but a clean comparison helps frame the conversation with a prescriber.

For a deeper look at how costs compare alongside effectiveness, the Mounjaro vs Wegovy price comparison sets out what private treatment typically costs at each dose. The full Wegovy vs Mounjaro overview also covers eligibility and NICE guidance in more detail.

Which should you choose, and what the consultation settles

The honest answer is that this decision belongs in a clinical conversation, not a comparison article. Several factors can shift the calculus: your current BMI, any existing health conditions, medicines you already take, your preference for injection frequency, and whether the oral Wegovy tablet option might suit you better than either injectable. Exploring the treatment options available through nume gives you a grounded starting point before that conversation.

A prescriber reviewing your full picture may have good reasons to consider whether Wegovy is less effective than Mounjaro for your specific situation, or to conclude the opposite, in ways that a trial average would never predict. The evidence is one input. That is exactly what the consultation is for, and why it is reviewed by a real clinician rather than processed automatically. Our clinical team follows this evidence closely and applies it to individual cases. If you have further questions before starting, the nume FAQs cover common eligibility and process queries.

Neither medicine is a guaranteed outcome. Both require a prescriber's assessment. People often ask whether Mounjaro is more effective than Wegovy before booking, and it is a reasonable question to bring to your consultation. Start your free consultation and the prescriber will work through the options with you.